Shaaltiel Yoseph

Protalix BioTherapeutics, Inc.

Executive VP, R&D

Avg. Two Year Performance

117% Avg. Purchase Return 47% Compound

21% Avg. Sale Return 10% Compound

Holdings: 795.92K shares

Last Three Months: 26-Aug-24 -- 25-Nov-24

0 Net Amount

Buy:	0	--
Sell:	0	--

Sentiment

Company Sentiment

Biotechnology

Drugs

Two Year Chart

26-Nov-22 -- 25-Nov-24

Price ($)

Two Year Stock Price Chart

Sentiment

Company Sentiment

Most Recent Insider Transactions